Quarterly report [Sections 13 or 15(d)]

In-licensing and Acquisition (Details)

v3.26.3
In-licensing and Acquisition (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 11, 2026
May 11, 2026
Feb. 22, 2024
Jun. 30, 2026
Jul. 31, 2024
Dec. 31, 2022
Jul. 31, 2022
Sep. 30, 2026
Mar. 31, 2023
Sep. 30, 2026
Jul. 30, 2026
Dec. 31, 2025
 [1]
Asset Acquisition [Line Items]                        
Accounts payable               $ 11,442   $ 11,442   $ 7,191
Estimated useful life                   13 years 6 months    
Acquisition-related liabilities               0   $ 0   $ 5,000
GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Estimated useful life     12 years                  
REZLIDHIA                        
Asset Acquisition [Line Items]                        
Estimated useful life                   14 years    
Blueprint | GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Asset acquisition, expected price     $ 15,000                  
Purchase consideration     15,400                  
Acquisition payment     15,000   $ 10,000              
Transaction costs     $ 400                  
Acquisition-related liabilities       $ 5,000                
Blueprint | GAVRETO (pralsetinib) | Minimum                        
Asset Acquisition [Line Items]                        
Potential tiered royalties     10.00%                  
Blueprint | GAVRETO (pralsetinib) | Maximum                        
Asset Acquisition [Line Items]                        
Potential tiered royalties     30.00%                  
Regulatory milestones | Blueprint | GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Potential milestone payments     $ 5,000                  
Commercial milestones | Blueprint | GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Potential milestone payments     97,500                  
First commercial sale | Blueprint | GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Asset acquisition, expected price     10,000                  
First anniversary of the closing date | Blueprint | GAVRETO (pralsetinib)                        
Asset Acquisition [Line Items]                        
Asset acquisition, expected price     $ 5,000                  
FDA approval and first commercial sale of product | REZLIDHIA                        
Asset Acquisition [Line Items]                        
Accounts payable           $ 15,000            
Arvinas And Pfizer                        
Asset Acquisition [Line Items]                        
Upfront fee   $ 85,000   $ 70,000                
Potential payments   15,000           12,500   $ 12,500    
Accounts payable               2,500   2,500    
Intangible assets capitalized $ 73,100                      
Estimated useful life 15 years                      
Arvinas And Pfizer | Regulatory milestones                        
Asset Acquisition [Line Items]                        
Potential payments   60,000                    
Arvinas And Pfizer | Commercial milestones                        
Asset Acquisition [Line Items]                        
Potential payments   260,000                    
Arvinas And Pfizer | Ongoing development activities                        
Asset Acquisition [Line Items]                        
Potential payments   $ 40,000                    
Research and development               $ 5,800   $ 7,300    
Forma                        
Asset Acquisition [Line Items]                        
Upfront fee             $ 2,000          
Research and development                 $ 2,000      
Forma | Commercial milestones                        
Asset Acquisition [Line Items]                        
Potential payments                     $ 165,500  
Forma | Development and regulatory milestones                        
Asset Acquisition [Line Items]                        
Potential payments                     $ 67,500  
Forma | Achievement of certain near-term regulatory milestone                        
Asset Acquisition [Line Items]                        
Research and development           $ 2,500            
[1] The balance sheet at December 31, 2025 has been derived from the audited financial statements included in Rigel’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 3, 2026.